Antiasthmatic prescriptions in children with and without congenital anomalies: a population-based study.
asthma
epidemiology
paediatrics
risk factors
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
13 10 2023
13 10 2023
Historique:
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
To explore the risk of being prescribed/dispensed medications for respiratory symptoms and breathing difficulties in children with and without congenital anomalies. A EUROlinkCAT population-based data linkage cohort study. Data on children with and without congenital anomalies were linked to prescription databases to identify children who did/did not receive antiasthmatic prescriptions. Data were analysed by age, European region, class of antiasthmatic, anomaly, sex, gestational age and birth cohort. Children born 2000-2014 in six regions within five European countries. 60 662 children with congenital anomalies and 1 722 912 reference children up to age 10 years. Relative risks (RR) of >1 antiasthmatic prescription in a year, identified using Anatomical Therapeutic Chemical classification codes beginning with R03. There were significant differences in the prescribing of antiasthmatics in the six regions. Children with congenital anomalies had a significantly higher risk of being prescribed antiasthmatics (RR 1.41, 95% CI 1.35 to 1.48) compared with reference children. The increased risk was consistent across all regions and all age groups. Children with congenital anomalies were more likely to be prescribed beta-2 agonists (RR 1.71, 95% CI 1.60 to 1.83) and inhaled corticosteroids (RR 1.74, 95% CI 1.61 to 1.87). Children with oesophageal atresia, genetic syndromes and chromosomal anomalies had over twice the risk of being prescribed antiasthmatics compared with reference children. Children with congenital anomalies born <32 weeks gestational age were over twice as likely to be prescribed antiasthmatics than those born at term (RR 2.20, 95% CI 2.10 to 2.30). This study documents the additional burden of respiratory symptoms and breathing difficulties for children with congenital anomalies, particularly those born preterm, compared with children without congenital anomalies in the first 10 years of life. These findings are beneficial to clinicians and healthcare providers as they identify children with greater morbidity associated with respiratory symptoms, as indicated by antiasthmatic prescriptions.
Identifiants
pubmed: 37832979
pii: bmjopen-2022-068885
doi: 10.1136/bmjopen-2022-068885
pmc: PMC10583066
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e068885Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Intensive Care Med. 1993;19(5):251-5
pubmed: 8408933
PLoS One. 2023 Aug 30;18(8):e0290711
pubmed: 37647348
BMJ Open Respir Res. 2018 Jan 08;5(1):e000260
pubmed: 29333271
PLoS One. 2022 Jul 22;17(7):e0269874
pubmed: 35867669
Allergol Immunopathol (Madr). 2018 May - Jun;46(3):210-217
pubmed: 27865539
BMJ Open. 2021 Jun 28;11(6):e047859
pubmed: 34183346
PLoS One. 2016 May 12;11(5):e0155556
pubmed: 27171167
Glob Pediatr Health. 2016 Sep 15;3:2333794X16668773
pubmed: 27689102
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Epidemiol Prev. 2005 Mar-Apr;29(2 Suppl):24-31
pubmed: 16128550
Eur Respir J. 2008 Oct;32(4):1096-110
pubmed: 18827155
J Perinatol. 2007 Sep;27(9):535-49
pubmed: 17637787
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Int J Pediatr Otorhinolaryngol. 2018 Jan;104:1-4
pubmed: 29287846
J Allergy Clin Immunol. 2006 Jan;117(1):184-9
pubmed: 16387604
Front Pediatr. 2018 Apr 20;6:109
pubmed: 29732364
Congenit Heart Dis. 2018 Nov;13(6):959-966
pubmed: 30242971
Pediatr Pulmonol. 2013 Feb;48(2):130-7
pubmed: 22451263
Eur Respir J. 2019 Apr 4;53(4):
pubmed: 30765507
Arch Dis Child. 1999 Nov;81(5):404-8
pubmed: 10519713
N Engl J Med. 1982 Nov 4;307(19):1170-3
pubmed: 6214715
Am J Respir Crit Care Med. 1997 Jan;155(1):174-80
pubmed: 9001308
Pediatr Allergy Immunol. 2012 Aug;23(5):464-71
pubmed: 22435792
BMJ. 2004 Oct 23;329(7472):962-5
pubmed: 15499114
Laeknabladid. 2011 Sep;97(9):463-7
pubmed: 21911911
Thorax. 2009 Jun;64(6):476-83
pubmed: 19237391
Eur J Clin Pharmacol. 2010 Mar;66(3):307-13
pubmed: 20187289
Birth Defects Res A Clin Mol Teratol. 2011 Mar;91 Suppl 1:S2-15
pubmed: 21384531
Eur Respir J. 1997 Aug;10(8):1780-6
pubmed: 9272919
Thorax. 2007 Sep;62(9):758-66
pubmed: 17504817
J Allergy Clin Immunol. 2015 Aug;136(2):360-6.e2
pubmed: 25828267
Eur Respir J. 2005 Jan;25(1):47-53
pubmed: 15640322
BMJ. 2000 Jan 8;320(7227):79-82
pubmed: 10625257
Eur Respir Rev. 2017 Feb 21;26(143):
pubmed: 28223397
Chest. 2004 Oct;126(4):1147-53
pubmed: 15486376
J Pediatr Surg. 1996 Feb;31(2):258-62
pubmed: 8938354
Pediatrics. 2016 Jan;137(1):
pubmed: 26712860
ERJ Open Res. 2017 Jul 03;3(3):
pubmed: 28845428
Interact Cardiovasc Thorac Surg. 2017 Oct 1;25(4):647-650
pubmed: 28595379
Pharmacol Res Perspect. 2023 Feb;11(1):e01037
pubmed: 36545691
BMJ Open. 2016 Jan 19;6(1):e009237
pubmed: 26787250
Eur Respir J. 2015 Aug;46(2):364-74
pubmed: 25537562